340B Reform Returns to Congress: What Cassidy's Discussion Draft Could Mean for Providers

For years, Washington has debated the 340B Drug Pricing Program without making meaningful legislative changes. Drug manufacturers argued the program had expanded far beyond its original intent. Hospitals and safety-net providers countered that the discounts had become essential to maintaining services in an increasingly difficult reimbursement environment. Meanwhile, litigation, agency guidance, and manufacturer policies gradually became the primary mechanisms shaping the program.

Against that backdrop, Senate HELP Committee Chairman Bill Cassidy recently released a discussion draft representing the most comprehensive congressional proposal to reform the program in years. Whether the legislation advances is uncertain, but the draft offers an important window into how policymakers are thinking about the future of 340B. Rather than simply preserving or dismantling the program, it raises broader questions about transparency, accountability, and whether current oversight matches the program's size and complexity.

What's striking is that the proposal does not hand either side a clear victory. Instead, it attempts to establish clearer rules around transparency, accountability, and patient benefit while preserving the program itself. Whether that balance satisfies either hospitals or manufacturers remains to be seen, but it marks a different approach than simply siding with one camp over the other.

The timing is significant because the program looks very different today than it did when Congress created it in 1992. The original goal was straightforward: allow qualifying safety-net providers to purchase outpatient drugs at discounted prices so they could stretch scarce federal resources and expand care for vulnerable patients.

Since then, however, the program has grown dramatically. According to HRSA, covered entities purchased approximately $81.4 billion in outpatient drugs through the program during 2024. Earlier Congressional Budget Office analysis found purchases through the Prime Vendor Program alone increased from $6.6 billion in 2010 to $43.9 billion by 2021. Much of that growth reflects broader shifts in healthcare, including hospital integration, expanding outpatient care, greater use of specialty medicines, and increased provider participation.

As the program expanded, so did the policy debate. Earlier disputes largely centered on whether manufacturers were complying with their statutory discount obligations. Today's debate is broader. Lawmakers are asking whether the program has enough guardrails to ensure savings are reaching patients and whether Congress should define those expectations more clearly.

Perhaps the most consequential provision gives manufacturers flexibility to provide 340B pricing through either traditional upfront discounts, retrospective rebates, or a federally administered claims repository. Rather than requiring every manufacturer to follow the same model, the legislation establishes multiple compliance pathways while creating standardized claims reporting requirements intended to reduce duplicate discounts and diversion.

The emphasis on claims data is not accidental. Over the past several years, disputes between manufacturers and covered entities have increasingly centered on data collection and verification. Several manufacturers have begun requiring detailed claims submissions before honoring discounts, arguing that additional documentation is necessary to protect program integrity.

Hospitals, by contrast, have generally viewed those policies as unilateral attempts to rewrite the program outside congressional authority. Instead of allowing those competing approaches to continue developing through litigation and administrative action, Cassidy's proposal would establish a statutory framework governing how claims are reported, verified, and reviewed.

Patient affordability sits at the center of the proposal. Hospital covered entities would be required to establish sliding-scale assistance policies that reduce out-of-pocket drug costs for qualifying patients. Depending on income, eligible patients could face no cost sharing or substantially reduced copayments for covered outpatient drugs. Other nonhospital covered entities would similarly be required to ensure patients are not denied medications because of their ability to pay.

That provision responds directly to one of the longest-running criticisms of the program. Critics have argued for years that 340B contains no explicit requirement that discounted drug prices translate into lower costs for individual patients. Supporters have countered that Congress intended the program to strengthen provider capacity rather than subsidize individual prescriptions.

Cassidy's proposal attempts to bridge those competing interpretations by preserving institutional flexibility while creating measurable patient affordability obligations.

Transparency is another area where the legislation breaks new ground. Large hospitals would face new disclosure obligations detailing 340B margins, charity care, payer mix, patient utilization, and how program resources are being used. Much of that information would become publicly available through HHS.

Those reporting provisions may ultimately prove just as consequential as the rebate reforms. Policymakers have debated for years whether 340B savings primarily support uncompensated care, community benefit programs, operating margins, or broader organizational investments. If enacted, these reporting requirements would provide Congress with considerably more information to evaluate those questions instead of relying largely on competing narratives from hospitals and manufacturers.

The legislation also addresses several long-running operational disputes involving contract pharmacies, child sites, third-party administrators, and audit authority. Taken together, those provisions would replace much of today's regulatory ambiguity with more detailed statutory requirements governing how the program operates.

Whether this discussion draft ultimately becomes law is another matter. Chairman Cassidy's remaining time in Congress is limited after losing his Senate primary, and any effort to move comprehensive 340B legislation would face significant political hurdles. The proposal also enters a debate where hospitals and pharmaceutical manufacturers continue to disagree on many of the core reforms, making consensus difficult even if Congress decides to take up the issue.

That uncertainty, however, does not diminish the draft's value. More than any previous congressional proposal in recent years, it brings together many of the issues that have driven litigation, administrative action, and industry disputes into a single legislative framework. Even if this specific bill never advances, it provides perhaps the clearest indication yet of the types of reforms Congress is likely to revisit in future 340B debates.

For providers, manufacturers, and organizations that support the program, the takeaway is not that sweeping reform is imminent. Rather, it is that the policy conversation is becoming more defined. Organizations that understand where lawmakers are focusing their attention today will be better positioned if and when Congress returns to 340B reform under a future chairman or a broader bipartisan effort.